the aid library

Key
Resources
Clinical
Guidelines
Women & Child
Health
Pharmacy &
Technologies
Public
Health
Capacity
Building
COUNTRIES
TOOLBOXES
- Conflict
- Zika
- TB
- Cholera
- HIV
- Polio
- Rapid Response
- Refugee
- Disability
- Specific Hazards
- Social Ethics
- Health Financing Toolbox

Middle East and North Africa
West and Central Africa
East and Southern Africa
South–East Asia Region
Western Pacific Region
Eastern Europe and Central Asia
Latin America and the Carribbean
Western and Central Europe
North America

Login
Register
English

Search database

Suggest new resources

Filter

107

Text search: omicron

Featured

Recommendations

New Publications

Language

English

Spanish

French

Arabic

Russian

Portuguese

Chinese

German

Document type

Guidelines

Studies & Reports

Fact sheets

Strategic & Response Plan

Situation Updates

Manuals

Infographics

Videos

No document type

Training Material

Countries / Regions

Brazil

Latin America and the Carribbean

Africa

Global

Mozambique

Ukraine

Philippines

South Africa

Argentina

Liberia

Nigeria

India

South Sudan

Germany

Syria

Chad

Western Pacific Region

Eastern Europe and Central Asia

Western and Central Europe

Venezuela

Eastern Europe

Southern Africa

Russia

Moldova

Authors & Publishers

World Health Organization WHO

World Health Organisation (WHO)

European Centre for Disease Prevention and Control ECDC

Organización Mundial de la Salud OMS

World Health Organization WHO, Regional Office of Africa

Office for the Coordination of Humanitarian Affairs OCHA

OPAS

Organisation Mondiale de la Santé OMS

Pan American Health Organisation PAHO

World Health Organization WHO, Regional Office of Europe

Africa CDC Centres for Disease Control and Prevention

African Union

et al.

OPS

Organização Mundial da Saúde (OMS)

WHO Europe

Anaya-Covarrubias, J.Y.

and P. Reijer

Gavi, the Vaccine Alliance

IHME Institut for Health Metrics and Evaluation

Institute for Health Metrics and Evaluation

Inter-agency Task Force on Financing for Development

Lowey, S.E.

Mauder, S.

MEDBOX Team

Ministerio da Saude Brasilia

National Department of Health, South Africa

OCHA Services reliefweb

Organisation mondiale de la santé (OMS)

Organización Mundial de Saude and OPAS

PAHO

Pan American Health Organization PAHO, World Health Organization WHO

Sachs, J., Karim, S., Aknin, L. et al.

Secretaria Extraordinária de Enfrentamento à COVID-19, Brasil

Syrian American Medical Society Foundation

The International Federation of Red Cross and Red Crescent Societies IFRC

The Lancet Commissions

United Nations (UN)

United Nations ECLAC

Vygen-Bonnet S, Koch J, Bogdan C, et al.

World Bank

World Health Organization (WHO), Regional Office of the Western Pacific

Publication Years

2020-2025

106

2010-2019

Global expenditure on health: Public spending on the rise?

World Health Organisation (WHO) (2021) C_WHO

The 2021 Report examines country health spending patterns and trends over the past 20 years, before the COVID-19 pandemic, with greater focus on public spending on health. The report also presents spending on primary health care, preliminary health expenditure in 2020 for a small set of countries (i ... ncluding their health spending on COVID-19) and an analysis of high-income countries spending patterns, in particular during the global financial crisis. The report also points out the need for more public investment in health to get progress towards UHC back on track and strong health security. more

Download

View PDF

Add to my MEDBOX

Infection prevention and control in the context of coronavirus disease (‎COVID-19)‎: a living guideline, 10 August 2023

World Health Organization WHO (2023) C_WHO

The Infection prevention and control in the context of coronavirus disease 2019 (COVID-19): a living guideline consolidates technical guidance developed and published during the COVID-19 pandemic into evidence-informed recommendations for infection prevention and control (IPC). This living guideline ... is available both online and PDF. **This version of the living guideline (version 5.0) **includes the following seven revised statements for the prevention, identification and management of SARS-CoV-2 infections among health and care workers: a good practice statement on national and subnational testing strategies; a good practice statement on passive syndromic surveillance of health and care workers; a good practice statement on prioritizing health and care workers for SARS-CoV-2 testing; a good practice statement on protocols for reporting and managing health and care worker exposures; a good practice statement to limit in-person work of health and care workers with active SARS-CoV-2 infections; a statement on high-risk exposures and quarantine; and, a conditional recommendation on the duration of isolation for health and care workers. Understanding the updated section Prevention of infections in the health care setting includes a multi-pronged and multi-factorial approach that includes IPC and occupational health and safety measures and adherence to Public Health and Social Measures in the community by the health workforce. The underlying infection prevention and control strategy of this section is the notion that early identification of symptomatic cases, testing and quarantining/isolating health and care workers decreases the risk of nosocomial infection to patients and to other health and care workers. more

Download

View PDF

Add to my MEDBOX

Clinical management of COVID-19: Living guideline, 18 August 2023

World Health Organisation (WHO) (2023) C_WHO

The WHO COVID-19 Clinical management: living guidance contains the most up-to-date recommendations for the clinical management of people with COVID-19. Providing guidance that is comprehensive and holistic for the optimal care of COVID-19 patients throughout their entire illness is important.

Download

View PDF

Add to my MEDBOX

Infection prevention and control in the context of coronavirus disease (‎COVID-19)‎: a living guideline, 9 October 2023

World Health Organization WHO (2023) CC

Download

View PDF

Add to my MEDBOX

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for ... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Add to my MEDBOX

Global technical consultation report on proposed terminology for pathogens that transmit through the air

World Health Organization WHO (2024) C_WHO

Terminology used to describe the transmission of pathogens through the air varies across scientific disciplines, organizations and the general public. While this has been the case for decades, during the coronavirus disease (COVID-19) pandemic, the terms ‘airborne’, ‘airborne transmission’ a ... nd ‘aerosol transmission’ were used in different ways by stakeholders in different scientific disciplines, which may have contributed to misleading information and confusion about how pathogens are transmitted in human populations. This global technical consultation report brings together viewpoints from experts spanning a range of disciplines with the key objective of seeking consensus regarding the terminology used to describe the transmission of pathogens through the air that can potentially cause infection in humans. This consultation aimed to identify terminology that could be understood and accepted by different technical disciplines. The agreed process was to develop a consensus document that could be endorsed by global agencies and entities. Despite the complex discussions and challenges, significant progress was made during the consultation process, particularly the consensus on a set of descriptors to describe how pathogens are transmitted through the air and the related modes of transmission. WHO recognizes the important areas where consensus was not achieved and will continue to address these areas in follow-up consultations. more

External Link

Add to my MEDBOX

Variantes del SARS-COV-2 (COVID-19) - Preguntas frecuentes

Pan American Health Organisation PAHO (2021) C_WHO

Create your own MEDBOX
Login

Home
Contact
Data privacy
Legal notice
FAQ
About
Sitemap

A Project by

dev-medbox @ 2025